What is Waymark?
Founded in 2021, Waymark operates at the intersection of healthtech and community care, providing a specialized platform that empowers providers to deliver high-quality, value-based care. The company distinguishes itself by deploying sophisticated software tools that identify care gaps and facilitate proactive patient engagement. By focusing on the community care sector, Waymark addresses critical inefficiencies in the healthcare delivery system, positioning itself as a vital partner for organizations seeking to improve population health metrics while managing costs effectively. Its market position is reinforced by a commitment to data-driven decision-making and a deep understanding of the complexities inherent in modern healthcare infrastructure.
How much funding has Waymark raised?
Waymark has raised a total of $87M across 2 funding rounds:
Series A
$45M
Other Financing Round
$42M
Series A (2022): $45M with participation from Andreessen Horowitz and New Enterprise Associates
Other Financing Round (2023): $42M led by Andreessen Horowitz, New Enterprise Associates, and Lux Capital
Key Investors in Waymark
Andreessen Horowitz
Founded in 2009, Andreessen Horowitz is a private American venture capital firm that invests in both early-stage start-ups and established growth companies. The company is headquartered in Menlo Park, California.
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California. New Enterprise Associates(NEA) is a venture capital firm focused on helping entrepreneurs build businesses.
Lux Capital
Lux Capital is a New York based venture capital firm that raises dedicated funds to invest in earlystage and growthstage companies at the intersection of science and technology, backing founders in frontier areas such as AI, robotics, space, defense, biotechnology, and advanced materials from seed through IPO or acquisition.
What's next for Waymark?
With the successful closure of its latest financing, Waymark is poised to scale its operational footprint and deepen its technological capabilities. The strategic allocation of these funds will likely prioritize the expansion of its provider network and the enhancement of its proprietary care management platform. As the healthtech landscape continues to consolidate, Waymark's ability to demonstrate measurable improvements in patient outcomes will be the primary driver of its long-term enterprise value. Investors are closely monitoring the company's ability to maintain its growth momentum while navigating the regulatory and operational challenges of the evolving healthcare sector. Future milestones will likely center on market penetration and the integration of new diagnostic and predictive features into its core service offering.
See full Waymark company page
